Categories: News

Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Dial-in information:
U.S. Toll-Free: 844-369-8774
International: 862-298-0844

A live webcast of the call will be available on the Caladrius website under the Investors & News section. A replay of the webcast will also be available for 90 days following the conclusion of the call.

For those unable to participate on the live conference call, an audio replay will be available that day starting at 7:30 p.m. (ET) until August 19, 2021, by dialing 877-481-4010 (U.S. Toll-Free) or 919-882-2331 (International) and by entering the replay passcode: 42180.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of  orphan designation for Buerger’s Disease in the U.S. as well as  SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the FDA to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).  For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com

Media:
Real Chemistry
Rachel Girard
Real Chemistry
Phone: 401-477-4030
Email: rgirard@realchemistry.com

Staff

Recent Posts

Avive Solutions Named #3 in Small and Mighty Category by Fast Company for the World’s Most Innovative Companies

Avive Solutions, Inc. joins the ranks of Waymo, Nvidia, Duolingo, and more SAN FRANCISCO, March…

13 minutes ago

RIFM Researcher Marissa Guttenberg, PhD, Receives SOT 2025 Best Paper of the Year Award

MAHWAH, N.J., March 19, 2025 /PRNewswire/ -- The Research Institute for Fragrance Materials (RIFM) congratulates…

13 minutes ago

Our Blood Institute Joins Velico’s Blood Center Education Program

BEVERLY, Mass., March 19, 2025 /PRNewswire/ --  19th March, Velico is pleased to announce that Our…

13 minutes ago

Landmark Study Explains Why Obesity Drugs Work Differently for Women and Men

Olio Labs Identifies Why Women Experience Stronger Side Effects from GLP-1 DrugsThe Company's AI-Powered Combination…

13 minutes ago

OsteoStrong Expands to Beverly Hills with New Location

Grand Opening Event to Highlight Cutting-Edge Bone Health and Strength Training Technology BEVERLY HILLS, Calif.,…

13 minutes ago

Gestalt and Primaa Collaborate to Revolutionize Skin Cancer Detection with AI-Powered Dermatopathology Tools

SPOKANE, Wash. and PARIS, March 19, 2025 /PRNewswire/ -- Gestalt, a leader in digital pathology…

13 minutes ago